Current guidelines recommend using either metronidazole or vancomycin to treat C. diff infections. “For many years the two antibiotics were considered to be equivalent in their ability to cure C. diff ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

A study has linked initial vancomycin monotherapy to higher rates of Clostridium difficile infection in patients with inflammatory bowel disease, according to a report by Internal Medicine News. The ...

A new study on Clostridioides difficile infections finds that choosing an alternative antibiotic for high-risk patients with pneumonia can reduce infection risk. C. diff infections can be deadly, and ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed. Conclusion ...

A new antibiotic to fight the deadly "superbug" C. diff has proved effective in clinical trials. Treating patients with ibezapolstat provided high rates of "sustained" clinical cures, say American ...

Am J Health Syst Pharm. 2012;69(11):933-943. Based on current clinical trials reporting fewer recurrences among patients treated with fidaxomicin in which the non-NAP1/BI/027 strains were isolated, ...

In a phase-one human clinical trial, a pharmacist researcher has demonstrated that a new antibiotic, called Omadacycline, may be a promising tool in combating the superbug known as C diff which causes ...

The antibiotic EVG7, developed in Leiden, has proven capable of fighting the dangerous gut bacterium C. difficile with only a minimal dose. What's more, the bacterium is far less likely to return, a ...

As the effectiveness of antibiotics meant to fight the deadly superbug Clostridioides difficile, or C. diff, wanes, a research team at the University of Houston is seeing positive results of a new ...